Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors
- PMID: 30894399
- DOI: 10.1136/gutjnl-2019-318650
Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors
Keywords: inflammatory bowel disease.
Conflict of interest statement
Competing interests: GGK has received honoraria for speaking or consultancy from Abbvie, Janssen, Pfizer and Takeda. He has received research support from Janssen, Abbvie, GlaxoSmith Kline, Merck and Shire. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE AND PBC. UTI Limited Partnership, assignee. Patent 62/555,397. 7 September 2017.
Comment on
-
Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression.Gut. 2019 Sep;68(9):1606-1612. doi: 10.1136/gutjnl-2018-317182. Epub 2018 Oct 18. Gut. 2019. PMID: 30337374
-
Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation?Gut. 2020 Mar;69(3):609-610. doi: 10.1136/gutjnl-2019-318444. Epub 2019 Feb 26. Gut. 2020. PMID: 30808645 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical